Latest News and Press Releases

Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and...

– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end – Formation of Clinical...

– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of PALI-2108 for the treatment of moderate-to-severe...

Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...

Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...

Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...

Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’s ROME, July 12, 2023 (GLOBE NEWSWIRE) -- IRBM,...

ROME, June 22, 2023 (GLOBE NEWSWIRE) -- IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD...

ROME, April 04, 2023 (GLOBE NEWSWIRE) -- IRBM, a drug discovery and early development research institute and global contract research organization, announces that it is joining the Chemical Biology...

NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...